NewAmsterdam Pharma (NASDAQ:NAMSW) Trading 8.9% Higher – Still a Buy?

Shares of NewAmsterdam Pharma (NASDAQ:NAMSW) shot up 8.9% on Friday . The company traded as high as $18.80 and last traded at $19.5930. 279 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 1,760 shares. The stock had previously closed at $17.99.

NewAmsterdam Pharma Price Performance

The business has a 50 day simple moving average of $22.76 and a two-hundred day simple moving average of $22.86.

Institutional Investors Weigh In On NewAmsterdam Pharma

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. purchased a new position in NewAmsterdam Pharma (NASDAQ:NAMSW) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,708 shares of the company’s stock, valued at approximately $397,000.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.